Immunic, Inc is developing and testing vidofludimus calcium, a lead drug candidate, showing potential to address key drivers of multiple sclerosis disease progression.
8 reports, 4 independent
Updated Sep 2
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 8
- Developments
- 4
- Repetition
- 62%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immunic, Inc is developing and testing vidofludimus calcium, a lead drug candidate, showing potential to address key drivers of multiple sclerosis disease progression.
How it developed
Newest first. Tap a step to see who reported it.Late-stage trials for vidofludimus calcium aim to redefine MS treatment.1 source
- Erik Lundgren joins Immunic as CEO, bringing experience from Genentech and leadership roles at Roche.Sub-event
Immunic, Inc is developing and testing vidofludimus calcium to address key drivers of MS progression.1 source
Immunic, Inc evaluated its drug candidate for PMS at the CMSC Annual Meeting.1 source
Coverage
Newest first; wire copies grouped- prnewswire.com
- proactiveinvestors.com
- yahoo.com
- proactiveinvestors.com
- prnewswire.com
- PR NewswireImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial
- Unknown outlet